• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    皇

    皇家布朗普顿医院

    Royal Brompton Hospital,Royal Brompton & Harefield NHS Foundation Trust
    EST. 1847
    1.1万论文总数
    47.1万引用总数

    论文量&引用量时间轴

    机构学者

    论文(10000)

    年份
    起
    –
    止
    排序
    1High-Flow Nasal Oxygen Therapy after Cardiac Surgery
    Edward Litton, Rachael L. Parke, Shay P. McGuinness, Sarah N. Dawson, Sofia S. Villar, Siddesh S. Shetty, Julia A. Fox-Rushby, Julieann Coombes,Richard Norman,Gavin J. Murphy,Jacquita S. Affandi, Aamer B. Ahmed,

    QuestionIn patients at increased risk of pulmonary complications undergoing cardiac surgery, does prophylactic high-flow nasal oxygen therapy (HFNOT) initiated at the time of extubation have important clinical benefits vs the use of standard oxygen therapy (SOT)?FindingsIn this randomized clinical trial that included 1280 adults, HFNOT did not improve clinical outcomes compared with SOT.MeaningThese findings do not support the routine implementation of prophylactic HFNOT for noninvasive respiratory support following cardiac surgery. This randomized clinical trial investigates the use of high-flow nasal oxygen therapy in patients at high risk of pulmonary complications following nonemergent cardiac surgery and assesses the clinical benefits of this technique compared with standard oxygen therapy. ImportanceHigh-flow nasal oxygen therapy (HFNOT) is used for noninvasive respiratory support following cardiac surgery despite uncertainty about its clinical effectiveness or associated costs.ObjectiveTo determine whether prophylactic HFNOT in patients at increased risk of respiratory complications following cardiac surgery has clinical benefits compared with standard oxygen therapy (SOT).Design, Setting, and ParticipantsThis adaptive, parallel group, randomized clinical trial collected and analyzed data from 17 cardiac surgery centers in 3 countries between October 7, 2020, and June 19, 2024. Eligible participants included adults undergoing nonemergent cardiac surgery with any of the following risk factors for pulmonary complications: chronic obstructive pulmonary disease, asthma, lower respiratory tract infection in the last 4 weeks, a body mass index of 35 or greater, or currently or recently smoking for longer than 10 pack-years. Outcome assessors were blinded. A preplanned sample size re-estimation was conducted after 300 participants completed the 90-day follow-up.InterventionParticipants were randomized at a 1:1 ratio with concealed allocation to HFNOT or SOT administered for at least 16 hours immediately after postoperative extubation.Main Outcomes and MeasuresThe primary effectiveness outcome was days alive and at home (DAH) without increased support compared with baseline in the first 90 days (DAH90). Any day of increased support, including at home, would provide a value of 0 for that day. Secondary outcomes included DAH90 without considering the additional support component.ResultsA total of 1280 patients were recruited (mean [SD] age, 62.9 [10.5] years; 892 [69.7%] men; 640 in each group), of whom 1224 (95.6%) had complete DAH90 data. The primary outcome of median DAH90 was 0 (IQR, 0-79) for the HFNOT group and 0 (IQR, 0-87) for the SOT group (median difference, 0 [95% CI, 0-0]; P = .75). Secondary clinical outcomes, including DAH90 without considering whether additional support was required, were similar between groups.Conclusions and RelevanceIn this randomized clinical trial of HFNOT in patients at increased risk of postoperative pulmonary complications after nonemergent cardiac surgery, HFNOT did not improve DAH90 without increased support. These findings do not support the implementation of routine prophylactic HFNOT after cardiac surgery.Trial Registrationisrctn.org Identifier: ISRCTN14092678

    2026JAMA NETWORK OPEN(2026)引用:13
    引用
    AI阅读
    加入学术空间
    2Explicit Differentiable Slicing and Global Deformation for Cardiac Mesh Reconstruction
    Yihao Luo, Dario Sesia,Fanwen Wang,Yinzhe Wu, Wenhao Ding, Kamrul Hasan,Jiahao Huang, Fadong Shi,Anoop Shah,Amit Kaura,Jamil Mayet,Guang Yang,

    Three-dimensional (3D) mesh reconstruction of the cardiac anatomy from medical images is useful for shape and motion measurements and biophysics simulations. However, 3D medical images are often acquired as 2D slices that are sparsely sampled (e.g., large slice spacing) and noisy, and 3D mesh reconstruction on such data is a challenging task. Traditional voxel-based approaches utilize non-differentiable pre- and post-processing that compromises fidelity to images, while mesh-level deep learning approaches require large 3D mesh annotations that are difficult to obtain. Differentiable cross-domain supervision from 2D images to 3D meshes is therefore crucial for enabling end-to-end optimization in medical imaging. While there have been attempts to approximate the voxelization and slicing of meshes that are being optimized, there has not yet been a method for directly using 2D slices to supervise 3D mesh reconstruction in a differentiable manner. Here, we propose a novel explicit differentiable voxelization and slicing (DVS) algorithm allowing gradient backpropagation to a 3D mesh from its slices, which facilitates refined mesh optimization directly supervised by the losses defined on 2D images. Further, we propose an innovative framework for extracting patient-specific left ventricle (LV) meshes from medical images by coupling DVS with a graph harmonic deformation (GHD) mesh morphing descriptor of cardiac shape that naturally preserves mesh quality and smoothness during optimization. The proposed framework achieves state-of-the-art performance in cardiac mesh reconstruction tasks from densely sampled (CT) as well as sparsely sampled (MRI stack with few slices) images, outperforming alternatives, including Marching Cubes, statistical shape models, algorithms with vertex-based mesh morphing algorithms and alternative methods for image-supervision of mesh reconstruction. Experimental results demonstrate that our method achieves an overall Dice score of 90% during a sparse fitting on multi-datasets. The proposed method can further quantify clinically useful parameters such as ejection fraction and global myocardial strains, closely matching the ground truth and outperforming the traditional voxel-based approach in sparse images.

    2026Medical image analysis(2026)引用:8
    引用
    AI阅读
    加入学术空间
    3A Game-Changing 20 Years: Progress and Future Directions in Lung Cancer Screening.
    Stephen Lam, David R Baldwin,Anand Devaraj,John Field,Claudia I Henschke,Marjolein A Heuvelmans, Rudolf M Huber,Catherine Jones,Andrea Borondy-Kitts, Molly Siu Ching Li,Renelle Myers,Raymond U Osarogiagbon,

    In the past two decades, lung cancer screening (LCS) with low-dose computed tomography (LDCT) has emerged as one of the most effective strategies for reducing lung cancer mortality. Landmark trials, including NLST and NELSON, demonstrated mortality reductions exceeding 20%, establishing LDCT as the standard of care for early detection in high-risk populations. Currently, 13 countries have implemented national or regional LCS programs, with additional nations preparing for rollout. Advances in risk-prediction models, volumetric nodule assessment, and structured management protocols have improved precision and efficiency. Integration of artificial intelligence is enhancing nodule detection, prediction of malignancy risk, individualized screening intervals, and workflow optimization. Real-world evidence confirms improved stage distribution and suggests reduction in lung cancer mortality. Initiatives such as promoting community engagement, equitable access through geospatial mapping, and mobile screening will improve screening uptake and retention. Embedding tobacco dependence treatment within LCS further augments life-years gained. Complementary incidental pulmonary-nodule programs and expanding studies in people who have never smoked are extending the reach of early detection, whereas biomarker research is progressing toward integration with imaging-based screening. The potential to use LDCT scans to detect coronary heart disease and chronic obstructive pulmonary disease may have a major impact on future health care benefits. Ongoing efforts to harmonize data collection standards, establish quality indicators, and strengthen workforce training are essential to sustain high-quality implementation. As LCS evolves into a cornerstone of lung cancer control, continued innovation in risk stratification, imaging technologies, and biomarker integration will be key to maximizing global benefit and equity.

    2026Journal of thoracic oncology official publication of the International Association for the Study of...(2026)引用:3
    引用
    AI阅读
    加入学术空间
    4Safety of Ultrasound-Guided Small-Bore Percutaneous Chest Drain Insertion in Cardiac Surgical Patients Receiving Dual Antiplatelet Therapy
    Naimish Adroja, Danial Saeed, Emeka Obasi, Simon P. G. Padley,Carole A. Ridge
    2026CardioVascular and Interventional Radiology(2026)引用:2
    引用
    AI阅读
    加入学术空间
    5High-Flow Nasal Oxygen Therapy after Cardiac Surgery: A Randomized Clinical Trial.
    Edward Litton, Rachael L Parke, Shay P McGuinness, Sarah N Dawson, Sofia S Villar, Siddesh S Shetty, Julia A Fox-Rushby,Julieann Coombes,Richard Norman,Gavin J Murphy,Jacquita S Affandi, Aamer B Ahmed,

    Importance:High-flow nasal oxygen therapy (HFNOT) is used for noninvasive respiratory support following cardiac surgery despite uncertainty about its clinical effectiveness or associated costs. Objective:To determine whether prophylactic HFNOT in patients at increased risk of respiratory complications following cardiac surgery has clinical benefits compared with standard oxygen therapy (SOT). Design, Setting, and Participants:This adaptive, parallel group, randomized clinical trial collected and analyzed data from 17 cardiac surgery centers in 3 countries between October 7, 2020, and June 19, 2024. Eligible participants included adults undergoing nonemergent cardiac surgery with any of the following risk factors for pulmonary complications: chronic obstructive pulmonary disease, asthma, lower respiratory tract infection in the last 4 weeks, a body mass index of 35 or greater, or currently or recently smoking for longer than 10 pack-years. Outcome assessors were blinded. A preplanned sample size re-estimation was conducted after 300 participants completed the 90-day follow-up. Intervention:Participants were randomized at a 1:1 ratio with concealed allocation to HFNOT or SOT administered for at least 16 hours immediately after postoperative extubation. Main Outcomes and Measures:The primary effectiveness outcome was days alive and at home (DAH) without increased support compared with baseline in the first 90 days (DAH90). Any day of increased support, including at home, would provide a value of 0 for that day. Secondary outcomes included DAH90 without considering the additional support component. Results:A total of 1280 patients were recruited (mean [SD] age, 62.9 [10.5] years; 892 [69.7%] men; 640 in each group), of whom 1224 (95.6%) had complete DAH90 data. The primary outcome of median DAH90 was 0 (IQR, 0-79) for the HFNOT group and 0 (IQR, 0-87) for the SOT group (median difference, 0 [95% CI, 0-0]; P = .75). Secondary clinical outcomes, including DAH90 without considering whether additional support was required, were similar between groups. Conclusions and Relevance:In this randomized clinical trial of HFNOT in patients at increased risk of postoperative pulmonary complications after nonemergent cardiac surgery, HFNOT did not improve DAH90 without increased support. These findings do not support the implementation of routine prophylactic HFNOT after cardiac surgery. Trial Registration:isrctn.org Identifier: ISRCTN14092678.

    2026JAMA network open(2026)引用:2
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 10000 篇论文

    合作机构(100)

    帝国理工学院合作论文 986
    皇家帕普沃思医院合作论文 173
    Royal Brompton & Harefield NHS Foundation Trust合作论文 165
    卢旺天主教大学合作论文 158
    爱丁堡大学合作论文 145
    牛津大学合作论文 138
    邓迪大学合作论文 122
    英国女王大学合作论文 121
    剑桥大学合作论文 120
    莱斯特大学合作论文 117

    机构统计